Wave Life Sciences price to sales ratio WVE

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 14.6×; Feb 2025
9-year median: 20.5×
9-year range: 1.8× to 197×
Peer median: 1.5×

Wave Life Sciences' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Feb 2025, at 14.6×.

On the days it had one over the last 9 years, its median was 20.5×, from 1.8× in May 2022 to 197× in Aug 2017.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	14.6×	14.6×	18.6×
2024	17.8×	4.5×	21.1×
2023	5.9×	5.1×	121×
2022	146×	1.8×	146×
2021	13.7×	13.7×	43.2×
2020	29.4×	14.2×	56.9×
2019	31.5×	30.4×	109×
2018	99.9×	87.7×	181×
2017	197×	197×	197×

Against its peers

Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.

Company	Price to sales ratio
WVEWave Life Sciences	n/m
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
IRWDIronwood Pharmaceuticals	1.5×
PBYIPuma Biotechnology	2.5×
COLLCollegium Pharmaceutical	0.9×
ARVNArvinas	1.5×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Wave Life Sciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.